FDA Examines Testosterone Use in Menopausal Women
The FDA examined testosterone use in menopausal women, including current evidence, safety questions, research gaps and potential future drug development.
FDA Approves Lynkuet (Elinzanetant): First Non-Hormonal Pill for Menopausal Hot Flashes
The FDA has approved Lynkuet (Elinzanetant), a groundbreaking non-hormonal medication that targets the brain pathways behind hot flashes. For women who can’t or prefer not to use hormone therapy, this represents a major step forward in menopause care.
New HRT Option Nalvee Launched in UK for Menopause Symptom Management
UK Approves First Testosterone Cream for Women: A Milestone in Menopause Care
UK approves first testosterone cream for postmenopausal women—sparking hope for future FDA approval in the U.S.
Elinzanetant Under FDA Review: A Potential New Non-Hormonal Option for Menopausal Symptoms
Elinzanetant (Lynkuet) is a new non-hormonal therapy under FDA review that could finally provide relief from hot flashes for women who can’t or prefer not to take hormone therapy. Promising trial results offer hope for midlife symptom relief.
New Non-Hormonal Treatment Offers Relief from Menopausal Hot Flashes — With Safety Caveats
Fezolinetant (Veozah) is the first non-hormonal drug approved to tackle menopausal hot flashes—but a rare liver injury warning means careful monitoring is essential. Could this new option finally provide relief for women who can’t or don’t want hormone therapy?
New Research Finds Early Menopause Hormone Therapy May Offer Big Benefits with Lower Risks
A major 2024 review of the Women’s Health Initiative has rewritten the story on hormone therapy. For women under 60 or within 10 years of menopause, the benefits may outweigh the risks—marking a turning point in how doctors and patients approach treatment.
Could a Weekly Pill Delay Menopause? Rapamycin Research Shows Promise
Could a weekly pill shift the menopause timeline? Researchers are exploring how one drug might change the future of women’s health.